Camurus Starts Phase 2b Trial of Monthly Semaglutide CAM2056 for Obesity
Camurus says it has dosed the first participant in the Phase 2b trial of monthly semaglutide CAM2056 for obesity.
Related stories
Keurig Dr Pepper Shares Fall About 4% on Slower Coffee Growth
The company flagged slower-than-expected growth in its US coffee segment for Q4.
M impact | EQUITY | Nov 03, 2026, 02:37 PM UTC
Volaris Shares Rise 10% at the Open
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Upwork raises annual adjusted profit forecast; shares rise 2.7%
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Proto Labs Raises Multi Jet Fusion 3D Printing Capacity by 50%
Proto Labs said it raised its HP Multi Jet Fusion 3D-printing capacity by 50%.
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Volaris shares surge 10% after opening
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
SBI shares fall 1.70% despite stronger Q2 performance
State Bank of India shares closed at Rs.970 after erasing intraday gains, despite September-quarter results coming in ahead of Street estimates.
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC